Blockchain Registration Transaction Record

Aditxt Validates Autoimmune Therapy Candidate ADI-100, Plans Regulatory Filings for Clinical Trials in 2025

Aditxt announces successful preclinical findings for ADI-100, showcasing its potential to induce immune tolerance in autoimmune conditions. Regulatory filings planned for 2025 mark progress towards clinical trials, offering hope for those with autoimmune diseases.

Aditxt Validates Autoimmune Therapy Candidate ADI-100, Plans Regulatory Filings for Clinical Trials in 2025

This news showcases the promising potential of Aditxt's lead autoimmune therapy candidate, offering hope for those with autoimmune conditions like type 1 diabetes. The validation of ADI-100's immune tolerance induction represents a significant step towards developing innovative health solutions.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x7506c4f626ac86fb57bcae2b22a732b4132fb20f50cfc8810eb4905dbbf69644
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintglueGqwp-05b186a75204ef8fdc26ecf1b051ea44